Jul 09, 2026, 10:43 AM ET, , , Summary Alnylam Pharmaceuticals stands to benefit from the unexpected Phase III failure of Ionis/AstraZeneca’s eplontersen, as it removes a key competitor in the ATTR-CM space. ALNY’s Amvuttra is positioned to capture potential billions in peak revenue previously modeled for Wainua, though better stabilizer performance may temper first-line and long-term combo usage.